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fibroblastic tumor stroma sustains curative
melanoma treatment
Sandra S. Ring1, Jovana Cupovic1,2, Lucas Onder1, Mechthild Lütge 1, Christian Perez-Shibayama1,
Cristina Gil-Cruz1, Elke Scandella1, Angelina De Martin1, Urs Mörbe 1, Fabienne Hartmann 1,
Robert Wenger3, Matthias Spiegl 3, Andrej Besse4, Weldy V. Bonilla5, Felix Stemeseder6, Sarah Schmidt6,
Klaus K. Orlinger6, Philippe Krebs 7, Burkhard Ludewig 1,8,11✉ & Lukas Flatz1,9,10,11✉
The tumor microenvironment (TME) is a complex amalgam of tumor cells, immune cells,
endothelial cells and fibroblastic stromal cells (FSC). Cancer-associated fibroblasts are
generally seen as tumor-promoting entity. However, it is conceivable that particular FSC
populations within the TME contribute to immune-mediated tumor control. Here, we show
that intratumoral treatment of mice with a recombinant lymphocytic choriomeningitis virus-
based vaccine vector expressing a melanocyte differentiation antigen resulted in T cell-
dependent long-term control of melanomas. Using single-cell RNA-seq analysis, we
demonstrate that viral vector-mediated transduction reprogrammed and activated a Cxcl13-
expressing FSC subset that show a pronounced immunostimulatory signature and increased
expression of the inflammatory cytokine IL-33. Ablation of Il33 gene expression in Cxcl13-
Cre-positive FSCs reduces the functionality of intratumoral T cells and unleashes tumor
growth. Thus, reprogramming of FSCs by a self-antigen-expressing viral vector in the TME is
critical for curative melanoma treatment by locally sustaining the activity of tumor-specific
T cells.
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The growth and differentiation of cancer cells in particularmicroenvironmental niches affects both disease progressionand the clinical success of cancer therapies. The tumor
microenvironment (TME) comprises various cell types including
immune cells as well as non-immune cells, such as blood and
lymphatic endothelial cells and fibroblastic stromal cells (FSCs)1,2.
The presence of tumor-infiltrating CD8+ T cells, CD4+ T helper
1 cells, and CD103+ DCs is associated with improved responses to
cancer immunotherapy3–5. Conversely, intratumoral accumula-
tion of regulatory T cells or immunosuppressive macrophages
inhibits antitumor immunity hindering the success of cancer
therapy6,7. Likewise, tumor-associated FSCs—usually referred to
as cancer-associated fibroblasts (CAFs)—have been considered as
a cancer-promoting cell population that facilitates cancer pro-
gression and metastasis, e.g., through synthesis of extracellular
matrix components, secretion of growth factors, cytokines, and
chemokines resulting in the formation of an immunosuppressive
environment8–11. However, tumor-associated FSC subsets can also
stimulate and support antitumor immunity and thus restrain
tumor growth12–15. Therapeutic approaches that target the
fibroblastic tumor environment, such as antibodies against TGF-β,
favor the development of an immune-inflamed TME and increase
the efficacy of checkpoint inhibitor therapy16–18. Thus, it is
important to elaborate therapeutic means that directly promote
the remodeling of the tumor FSC landscape and thereby elicit an
immune-inflamed state in the TME.
Following Coley’s initial observation19, a number of approaches
have been developed to generate an inflammatory environment in
the tumor (reviewed in ref. 20,21). Oncolytic herpes viruses, for
example, are designed to infect cancer cells and to elicit cancer cell
apoptosis, which stimulates both presentation of tumor antigens and
recruitment of immune cells to the tumor site22. Genetic modifica-
tion of viral vectors through expression of immunostimulatory
cytokines, such as colony-stimulating factor 2 (granulocyte-macro-
phage colony-stimulating factor) is used to overcome immunosup-
pressive processes in the TME through the stimulation of myeloid
cells23. However, myeloid cell turnover in tumors is fast24 and
reprogramming of the TME via this axis might dampen sustenance
of immune system-activating circuits in the TME. Hence, viral
vector-mediated transduction of long-lived cells in the TME, such as
FSCs that provide activating stimuli to tumor-infiltrating lympho-
cytes would provide a solution to the conundrum. The non-
cytopathic lymphocytic choriomeningitis virus (LCMV) infects a
broad range of host cells including myeloid cells, epithelial cells,
endothelial cells and fibroblasts25–29. LCMV-based viral vectors elicit
strong and multifunctional CD8+ T cell responses following intra-
venous application30,31. Clinical trials using intramuscular application
of the vector have been initiated32. However, it is not known whether
and to what extent intratumoral delivery of LCMV-based vectors
impacts the TME and the outcome of the vaccination.
Here, we show that a single intratumoral application of an
LCMV-based vaccine vector expressing the melanoma-associated
antigen TRP2 facilitates curative melanoma treatment. Trans-
duction of tumor-associated FSCs by the viral vector precipitates
profound activation and reprogramming of immunostimulatory
Cxcl13-expressing FSCs. We demonstrate that IL-33 catered by
Cxcl13-Cre+ FSCs to tumor-infiltrating CD8+ T cells reduces
local T cell exhaustion and thereby sustains control of tumor
growth. In sum, our study shows that viral vector-mediated
remodeling of the FSC landscape in the TME is crucial for suc-
cessful tumor immunotherapy.
Results
Intratumoral artLCMV-TRP2 treatment controls melanoma
growth. Locally replicating LCMV strains, such as LCMV
Armstrong induce robust CD8+ T cell responses that rapidly
clear the virus33. Here, we used LCMV-based, propagation-
attenuated recombinant LCMV vectors with an artificial genome
organization (artLCMV)31 expressing the murine melanocyte
differentiation antigen TRP2 (artLCMV-TRP2) to treat orthoto-
pically growing B16F10 melanomas (Fig. 1a). Therapeutic intra-
tumoral (i.t.) treatment of established melanomas on day 7 with
artLCMV-TRP2 led to tumor regression in all mice with long-
term cure in ~60% of the mice, in a dose-independent manner
(Fig. 1b, c, Supplementary Fig. 1a). In contrast, mice treated
intravenously (i.v.) with artLCMV-TRP2 failed to eliminate the
tumors, despite a transient delay in tumor growth (Fig. 1b, c).
Curative i.t. treatment with artLCMV-TRP2 was dependent on
self-antigen expression by the tumor cells and self-antigen-
delivery by the vector, as demonstrated by the failure to eliminate
TRP2-deficient tumor cells (B16F10-Dct−/−, Fig. 1d and Sup-
plementary Fig. 1b) and the lack of long-term tumor control
when artLCMV vectors expressing irrelevant antigens were
applied (artLCMV-green fluorescent protein (GFP), Fig. 1e).
Antibody-mediated T cell depletion revealed that both CD4+ and
CD8+ T cell subsets were necessary to reject the tumor indicating
that the antitumor effect of artLCMV-TRP2 treatment was
mediated by TRP2-specific T cells (Fig. 1f and Supplementary
Fig. 1c). Mice that had received curative artLCMV-TRP2 treat-
ment were protected from re-challenge with B16F10 melanomas
into the opposite flank, provided that these animals were T cell-
competent (Fig. 1g). Mice cured of melanomas after i.t.
artLCMV-TRP2 treatment showed vitiligo-like fur depigmenta-
tion at the tumor site (Supplementary Fig. 1d), suggesting that
vector-mediated delivery of a melanocyte-specific antigen has
caused a highly effective immune response. To strengthen
translational relevance of our approach, we utilized a multi-
metastatic model in which tumors grow simultaneously ortho-
topically in the skin and in the lung (Fig. 1h). Mice treated with
artLCMV-TRP2 i.t. into the accessible s.c. tumor exhibited sig-
nificantly reduced metastatic tumor growth in the lung compared
to control mice. This finding suggests that artLCMV-induced
antitumor immunity is not restricted to the injected tumor but
also constrains tumor growth in peripheral tissues (Fig. 1i). In
sum, these data demonstrate that i.t. artLCMV-TRP2 elicits
therapeutically effective TRP2-specific T cell responses that
control a metastasizing tumor and provide long-term protection
from recurring melanomas.
To further elaborate the immunological mechanisms under-
lying the tumor-protective treatment, we followed the accumula-
tion and functional differentiation of intratumoral T cells. Both,
i.v. and i.t. artLCMV-TRP2 injection led to a significant increase
of CD8+ T cell accumulation compared to PBS treatment, while
CD4+ T cell infiltration was favored by the i.t. route (Fig. 2a, b
and Supplementary Fig. 2a–c). Intratumoral artLCMV-TRP2
vector application not only enhanced CD8+ T cell accumulation,
but significantly bolstered IFN-γ- and granzyme B-expression
compared to i.v. treatment (Fig. 1c, d and Supplementary Fig. 2d).
Likewise, IFN-γ production of tumor-infiltrating CD4+ T cells
was significantly increased in i.t. compared to i.v. artLCMV-
TRP2-treated mice (Fig. 1c and Supplementary Fig. 2e). CD8+ T
cell activity in the TDLN was not affected by the vaccination
route (Supplementary Fig. 2f). Overall, these data suggest that i.t.
artLCMV-TRP2 injection affects mainly the TME and thereby
sustains the functionality of tumor-infiltrating T cells.
artLCMV-TRP2 targets the fibroblastic tumor stroma. To
gauge the artLCMV vector-induced alterations in the TME, we
first followed the temporal and spatial dissemination of the
artLCMV vectors after i.t. injection. Analysis of viral
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nucleoprotein (LCMV-NP) RNA expression revealed the persis-
tence of the vector in the tumor tissue with minor spread to the
tumor-draining lymph node (TDLN), remote non-draining
lymph nodes or the spleen (Fig. 3a). Flow cytometric analysis
of single-cell suspensions at day 11 showed that the LCMV-NP
protein was broadly distributed with high expression in PDPN-
expressing FSCs and in B16F10 tumor cells (marked by the
mCherry reporter), while a significantly lower proportion of
CD45+ immune cells and CD31+ blood endothelial cells har-
bored the viral antigen (Fig. 3b, c, Supplementary Fig. 3a, b). In
comparison, i.v. artLCMV vector application led only to low or
moderate transduction of cells in the TME (Supplementary
Fig. 3b, c). Confocal microscopy analysis confirmed the presence
of LCMV-NP in melanoma cells (Fig. 3d, arrows) and in PDPN+
FSCs located mainly at the tumor margin (Fig. 3d, arrowheads).
FSCs isolated from human skin and melanoma biopsies could be
readily infected with artLCMV vaccine vectors (Fig. 3e, f) with the
majority of LCMV-NP+ FSCs showing co-expression of CD90
(Thy1) and PDPN (Fig. 3g, Supplementary Fig. 3d, e). In contrast,






































































































































































































Fig. 1 Melanoma growth after intratumoral artLCMV-TRP2 treatment. a Schematic depiction of the recombinant artLCMV vector expressing the melanocyte
differentiation antigen TRP2 (artLCMV-TRP2) and treatment scheme. b Tumor growth with indication of number of tumor-free mice and c survival of mice treated
intratumorally (i.t.) or intravenously (i.v.) with artLCMV-TRP2. d Tumor kinetics of B16F10 and TRP2-deficient B16F10 (B16F10-Dct−/−) in mice immunized i.t. with
artLCMV-TRP2. e Tumor growth with indication of number of tumor-free mice of mice treated i.t. with artLCMV-TRP2 or -GFP. f Tumor growth in mice
administered with anti-CD8- and anti-CD4-depleting antibodies and treated i.t. with artLCMV-TRP2. g Surviving mice from c were re-challenged with B16F10 s.c.
into the opposite right flank. In one cohort of mice, CD8- and CD4-depleting antibodies were administered. h, iMice were inoculated with s.c. B16F10 on day 0 and
i.v. on day 3 to establish pulmonary melanoma metastasis. On day 7, mice were treated i.t. with artLCMV-TRP2 and on day 17 lungs were harvested. Analysis of
lungs for pulmonary tumor metastasis with representative images (h) and quantification (i). Dots indicate mean ± s.e.m. values for each time point. Pooled data
from three independent experiments with n= 14 (PBS), n= 13 (artLCMV-TRP2, i.v.) and n= 15 (artLCMV-TRP2, i.t.) mice (b, c), n= 15 (Untreated), n= 13
(Survivors) and n= 7 (Survivors+ α-CD8/α-CD4) mice (g); n= 10 (PBS, i.t.) and n= 11 (artLCMV-TRP2, i.t.) mice (i). Pooled data from two independent
experiments with n= 9 (B16F10, PBS), n= 6 (B16F10-Dct−/−, PBS), n= 14 (B16F10, artLCMV-TRP2, i.t.) and n= 7 (B16F10-Dct−/−, artLCMV-TRP2, i.t.) mice (d);
n= 10 (PBS), n= 9 (artLCMV-GFP, i.t.) and n= 9 (artLCMV-TRP2, i.t.) mice (e); n= 9 (PBS), n= 11 (artLCMV-TRP2, i.t.) and n= 10 (artLCMV-TRP2, i.t.+α-CD8/
α-CD4) mice (f). Statistical analysis was performed using two-way analysis of variance (ANOVA) with Bonferroni (b, d, e, f), Log-Rank Mantel–Cox test (c, g), or
unpaired two-tailed Student’s t test (i) with *P<0.05: **P <0.01; ***P <0.001. Source data and exact P values are provided in the Source data file.
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transduction rate (Fig. 3f) with mainly myeloid cells harboring
the viral protein (Supplementary Fig. 3g, h). These data indicate
that both murine and human melanoma-derived FSCs can be
targeted efficiently by the artLCMV vector.
Intratumoral application of artLCMV vectors changed the
non-hematopoietic tumor stroma with a significantly increased
proportion of PDPN+ FSCs (Fig. 4a), while the fractions of CD31
+ blood endothelial cells and PDPN-negative FSCs cells were
reduced (Supplementary Fig. 4a–c). The stromal cell composition
in the TDLN was not affected by the i.t. artLCMV vector
treatment (Supplementary Fig. 4b, d). PDPN-expressing tumor
FSCs were activated by the artLCMV injection with significantly
enhanced expression of MHC class I molecules (H2-Kb and Db),
intercellular adhesion molecule 1 and vascular cell adhesion
molecule 1 (Supplementary Fig. 4e). Moreover, intratumoral
artLCMV application induced a significant increase in gene
expression of lymphocyte-attracting chemokines Cxcl13 and
Ccl19 in PDPN+ FSCs (Fig. 4b). The remodeling of the FSC
landscape with the acquisition of immunostimulatory properties
was confirmed in Cxcl13-Cre/tdTomato R26R-EYFP (abbreviated
as Cxcl13-Cre/tdTom EYFP) mice. In this transgenic mouse
model, Cre recombinase expression is controlled by the Cxcl13
promoter and facilitates labeling of cells with current or past
Cxcl13 expression or the progeny of chemokine-expressing cells
with EYFP. In addition, expression of the real-time reporter
tdTomato is under the control of the Cxcl13 promoter allowing
detection of current Cxcl13 expression mice34,35. Microscopic
analysis of B16F10 tumors growing in Cxcl13-Cre/tdTomato
EYFP mice revealed that lineage-traced EYFP+ cells localized
mainly in the tumor margin co-express PDPN both in PBS- and
artLCMV-treated tumors (Fig. 4c, arrowheads). Flow cytometry-
based quantification of tumor fibroblasts showed that artLCMV-
TRP2 treatment precipitated a significant expansion of PDPN+
EYFP+ FSCs (Fig. 4d), while the proportion of EYFP+ PDPN+
FSCs in TDLNs remained unchanged (Supplementary Fig. 4f).
Importantly, current expression of CXCL13 as determined by the
tdTomato reporter was significantly increased in tumor fibro-
blasts following artLCMV-TRP2 treatment, but was not affected
in TDLNs (Fig. 4e, Supplementary Fig. 4g). In sum, these data
indicate that the transduction of TME-associated PDPN+ FSCs
by artLCMV-TRP2 promotes the activation of immunostimula-
tory, Cxcl13-expressing PDPN+ FSCs.
artLCMV-TRP2 application reprograms the fibroblastic tumor
stroma. To resolve the molecular circuits underlying the
artLCMV-induced activation of FSCs in the TME, we isolated
FSCs from tumors of Cxcl13-Cre/tdTom EYFP mice and per-
formed droplet-based single-cell RNA sequencing (scRNA-seq;
Supplementary Fig. 5a). Unsupervised clustering of EYFP-
expressing cells using Uniform Manifold Approximation and
Projection (UMAP) revealed six conserved FSC clusters (Fig. 5a).
Based on hierarchical clustering with computation of cluster-
specific genes (Supplementary Fig. 5b) and the expression of
canonical FSC markers (Supplementary Fig. 5c), we discerned
transcriptional signatures associated with two clusters of
inflammatory cancer-associated fibroblasts (iCAF1 and iCAF2)
expressing Dpp4, Cd34, Ly6c1, and Ly6a (Fig. 5b). These parti-
cular populations phenotypically resemble iCAFs present in
murine and human pancreatic ductal adenocarcinoma13,36.
Moreover, we distinguished two clusters of myofibroblasts
(myCAF1 and myCAF2) characterized by high expression of
Col15a1, Tgfb1, Lrrc15, and the MHC II molecule H2-Ab1 in
myCAF2 (Supplementary Fig. 5d). Expression of ECM genes in
the myCAF1 population suggests a more structural role through
the production of collagen networks. MyCAFs2 express potential
immune-regulatory genes as well as genes associated with hypoxia
and metabolic regulatory pathways, recently described as VEGF+













































































































Fig. 2 T cell activity after intratumoral artLCMV-TRP2 treatment. a–d B16F10-tumor bearing mice were treated on day 7 with artLCMV-TRP2 i.v. or i.t.
Flow cytometric analysis of tumor-infiltrating T cells on day 15: Representative plots (a) and quantification of CD8+ and CD4+ T cell frequency (b). c IFN-
γ-producing CD8+ and CD4+ T cells. Granzyme B-expressing CD8+ T cells (d) with representative plots (e). Dots represent individual mice and lines
indicate mean values. Pooled data from two independent experiments with n= 6 (PBS), n= 13 (artLCMV-TRP2, i.v.) and n= 11 (artLCMV-TRP2, i.t.) mice
(b); n= 9 (artLCMV-TRP2, i.v. and i.t.) mice (c, d). Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (b) or
unpaired two-tailed Student’s t test (c, d) with *P < 0.05: **P < 0.01; ***P < 0.001. Source data and exact P values are provided in the Source data file.
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Rgs5 and Des (Supplementary Fig. 5e) and a cluster of fibroblasts
enriched in cell cycle genes including Mki67, Cks2, and Cdc20
(proliferating CAFs, Supplementary Fig. 5b, f). Detailed analysis
of EYFP+ FSCs unveiled a substantial shift in the abundance of
the iCAF1 and iCAF2 clusters in artLCMV-treated tumors,
whereas the relative abundance of the other clusters was largely
preserved (Fig. 5c). Flow cytometric analysis for CD26 (Dpp4)
and CD34 expression confirmed that iCAFs represent a sub-
stantial fraction of the EYFP+ PDPN+ tumor fibroblasts and that
the subsets of Ly6C+ CD34+ and Sca-1+ CD34+ fibroblasts were
significantly expanded after artLCMV treatment (Fig. 5d and
Supplementary Fig. 5g).
Computation of differential gene expression for the iCAF
clusters under artLCMV treatment vs. PBS control revealed
distinct sets of immunostimulatory pathways (Supplementary
Fig. 6a). Moreover, we found an iCAF signature (Supplementary
Fig. 6b) that was particularly strong in the iCAF2 cluster as
revealed by the alignment of the individual cells of all clusters
along their trajectories in diffusion maps (Fig. 5e). The distinct
immunostimulatory gene signatures, i.e., cell activation, chemo-
kine and cytokine expression (Fig. 5f), antigen presentation, and
type I interferon, and interferon-stimulated genes (Supplemen-
tary Fig. 6c), mapped preferentially to the iCAF subsets. The
expression of the chemokine gene Cxcl13 was almost exclusively
restricted to FSCs in the iCAF2 cluster both in PBS- and
artLCMV-injected tumors (Fig. 5g). TdTomato+ cells in tumors
of artLCMV-TRP2-treated Cxcl13-Cre/tdTom EYFP mice
belonged mainly to the Ly6C+ CD34+ and Sca-1+ CD34+
subsets, which is compatible with the iCAF signature (Supple-
mentary Fig. 6d). Global analysis of differentially regulated genes
under artLCMV- vs. PBS-treatment in the iCAF clusters high-
lighted Il33 as a potential candidate for the local stimulation of
T cells (Fig. 5h). The increased expression of Il33 in EYFP+
PDPN+ FSCs following artLCMV application was validated by
real-time PCR analysis (Fig. 5i). Moreover, microscopic analysis
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Fig. 3 Transduction of PDPN+ FSCs in the TME by intratumoral artLCMV-TRP2 application.Mice were inoculated with B16F10-mCherry and immunized
i.t. on day 7 with artLCMV-TRP2. a LCMV-NP RNA expression in tumor, tumor-draining, and non-draining lymph nodes (TDLN and NDLN) and spleen at
indicated time points after i.t. artLCMV-TRP2 treatment. Dots indicate mean±s.e.m. for each time point. b, c Flow cytometric analysis with representative
tSNE plot gated on viable Ter119− cells on day 11. b Expression of indicated marker and c frequency of LCMV-NP+ cells among identified cell populations in
the TME including: mCherry+ tumor cells, CD45+ immune cells, PDPN+ FSCs, and CD31+ BECs. Dots represent individual mice and lines indicate mean
values ± s.e.m values. d Representative confocal microscopy of tumors on day 11 following i.t. artLCMV-TRP2 injection from n= 3 mice. Representative
areas are shown: (i) in the center of the tumor and (ii) in the tumor margin. Arrows and arrowheads indicate artLCMV-transduced cells by positive staining
for LCMV-NP. Scale bar 1000 μm (overview) and 10 μm (boxed areas). e–g Infection of FSCs from human skin and melanoma biopsies with artLCMV.
Scale bar 50 μm. e Representative high resolution immunofluorescence images of artLCMV-transduced human skin-derived FSCs. f Frequency of LCMV-
NP+ cells. g Frequency of CD90+ PDPN+ and CD90+ PDPN− cells among LCMV-NP+ FSCs. Dots represent individuals and lines indicate mean values ± s.
e.m values. Pooled data from two independent experiments with n= 11 mice (a) and n= 8 mice (c). Pooled data from n= 6 (PBMCs and Skin Fibroblasts)
and n= 2 (Melanoma Fibroblasts) patients (f) and n= 7 patients (g). Statistical analysis was performed using two-way analysis of variance (ANOVA) with
Bonferroni (a), one-way ANOVA with Tukey’s multiple comparison test (c), or unpaired two-tailed Student’s t test (f, g) with *P < 0.05: **P < 0.01; ***P <
0.001. Source data and exact P values are provided in the Source data file.
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Cxcl13-Cre/tdTom EYFP mice revealed cytokine-positive EYFP+
cells at the tumor margin (Supplementary Fig. 6e). In sum, these
data indicate that intratumoral artLCMV application reprograms
the tumor-associated FSC landscape leading to a pronounced
shift towards an immunostimulatory cell state in iCAFs resulting
in a higher abundance of the iCAF2 subset.
FSC-derived IL-33 prevents intratumoral T cell exhaustion.
Since tumor FSCs exhibited increased IL-33 production after
artLCMV-TRP2 injection, we considered it likely that CD8+ T cells
respond locally to this cytokine. Indeed, tumor-infiltrating CD8+
T cells showed elevated expression of the IL-33 receptor ST2, while
ST2 expression on CD8+ T cells in the TDLN remained low (Fig. 6a
and Supplementary Fig. 7a). To further assess to which extent FSC-
derived IL-33 in the TME affects treatment efficacy, we crossed
Cxcl13-Cre/tdTom mice to Il33fl/fl (Cxcl13-Cre Il33fl/fl) mice. Tumor
growth and survival were similar in PBS-injected Cre-negative lit-
termate Ctrls and Cxcl13-Cre Il33fl/fl mice. Moreover, while intratu-
moral artLCMV-TRP2 treatment of Ctrl mice promoted tumor
control and cured four out of nine mice in long-term, Cxcl13-Cre
Il33fl/fl mice failed to control the tumors (Fig. 6b, c). Analysis of the
tumoral immune cell milieu revealed decreased frequencies of tumor-
infiltrating CD8+ T cells on day 15 after i.t. artLCMV-TRP2 treat-
ment in Cxcl13-Cre Il33fl/fl compared with Ctrl mice, whereas the
abundance of other immune cell subsets was not substantially affected
(Fig. 6d and Supplementary Fig. 7b, d). Notably, the frequency of
CD8+ and CD4+ T cells in the TDLN was not altered due to the Il33-
deficiency in Cxcl13-Cre+ FSCs (Supplementary Fig. 7e, f). Further
flow cytometric analyses revealed decreased frequencies of TRP2-
specific, tetramer-binding CD8+ T cells in tumors from Cxcl13-Cre
Il33fl/fl mice (Fig. 6e), a reduction of KLRG1+ CD62L− CD8+ T cells
(Fig. 6f and Supplementary Fig. 7g), and significantly impaired CD8+
T cell effector function as demonstrated by the reduced expression of
IFN-γ and TNF-α following ex vivo restimulation with TRP2 peptide
(Fig. 6g). In addition to the loss of CD8+ effector T cells, the lack of
Il33 expression in Cxcl13-Cre+ FSC in the TME led to an increase of
exhausted CD8+ T cells with higher abundance of CD69-expressing
cells (Fig. 6h and Supplementary Fig. 7h), elevated expression of the
exhaustion markers PD-1, Eomes, TOX, but not T-bet, in CD8+
T cells (Fig. 6i), increased abundance of PD-1high Eomeshigh CD8+
T cells (Fig. 6j and Supplementary Fig. 7i) and PD-1high TOXhigh
CD8+ T cells (Fig. 6k and Supplementary Fig. 7j). Importantly, we
did not find differences in the expression of CD8+ T cells exhaustion
markers in the TDLN between Ctrl and Cxcl13-Cre Il33fl/fl mice
(Supplementary Fig. 7k). Moreover, the production of effector cyto-
kines in adoptively transferred P14 T cells (T cell receptor transgenic
CD8+ T cells specific for the LCMV epitope GP33-41) was sig-
nificantly decreased by Il33-ablation in Cxcl13-Cre+ tumor FSCs and
deficiency of the IL-33 receptor ST2 on transferred P14 T cells
(Supplementary Fig. 8a–c).
To further assess whether local application of the LCMV vector
impacts T cell responses in the draining lymph node, we infected
Cxcl13-Cre Il33fl/fl and Cre-negative Ctrl mice subcutaneously
with artLCMV-TRP2 (Supplementary Fig. 9a). Analysis of the
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Fig. 4 artLCMV treatment induces Cxcl13-expressing FSCs in the TME. Mice were inoculated with B16F10-mCherry and immunized i.t. on day 7 with
artLCMV-TRP2 and tumors were analyzed on day 11. a Frequency of PDPN+ cells in tumors from mice treated i.t. with artLCMV-TRP2. b Quantitative real-
time PCR for Ccl19 and Cxcl13 mRNA expression in PDPN+ FSCs sorted from tumors on day 11. c Confocal microscopy of tumors from Cxcl13-Cre/tdTom
EYFP mice treated as indicated. Scale bars 700 μm (overview) and 80 μm (boxed areas). Arrowheads indicate EYFP+ PDPN+ FSCs. d Frequency of EYFP+
PDPN+ in Cxcl13-Cre/tdTom EYFP mice. e Frequency of tdTom+ cells among EYFP+ PDPN+ cells as marker for current CXCL13 expression. Dots
represent individual mice and lines indicate mean values ± s.e.m values. Pooled data from two independent experiments with n= 7 (PBS) and n= 6
(artLCMV-TRP2) mice (a, d, e); n= 7 (Ccl19, PBS; Ccl19, artLCMV-TRP2; Cxcl13, artLCMV-TRP2) and n= 6 (Cxcl13, PBS) mice (b). Representative images
from n= 4 (PBS) and n= 5 (artLCMV-TRP2) mice (c). Statistical analysis was performed using unpaired two-tailed Student’s t test (a, b, d, e) with *P <
0.05: **P < 0.01; ***P < 0.001. Source data and exact P values are provided in the Source data file.
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did not reveal significant differences in the frequency of CD8+
T cells (Supplementary Fig. 9b), or TRP2- and LCMV (GP33 and
NP396)-specific CD8+ T cell cytokine responses between Cxcl13-
Cre Il33fl/fl and Cre-negative Ctrl mice (Supplementary Fig. 9b, f).
These data indicate that IL-33 is dispensable for the activation of
CD8+ T cell effector function in the SDLN after local artLCMV-
TRP2 immunization. Collectively, we conclude that IL-33 catered
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Fig. 5 Activation of Cxcl13-expressing immune-stimulatory FSCs by intratumoral artLCMV-TRP2 treatment. Single-cell RNA-seq analysis of EYFP+ cells
isolated from the tumors of Cxcl13-Cre/ tdTom EYFP mice treated i.t. with artLCMV-TRP2 or PBS on day 11. a UMAP plots displaying FSCs cluster
assignment in PBS control or artLCMV-treated mice. b Violin plots depicting expression of iCAF marker genes Ly6c1, Ly6a, Cd34, and Dpp4. c Pie charts
showing the relative abundance of the identified FSC clusters. d Flow cytometric analysis of EYFP+ PDPN+ cells stained for CD26 (Dpp4), CD34, Ly6C
(Ly6c1), and Sca-1 (Ly6a/ Ly6e). e, f Diffusion maps of EYFP+ tumor FSCs with trajectories constructed based on differential genes analysis in clusters
iCAF1 and iCAF2 between PBS and artLCMV condition. e Diffusion maps showing subset clustering and iCAF signatures and f cell activation signature and
chemokine and cytokine signature. g UMAP feature plots of Cxcl13 expression. h Scatter plot depicting DE genes of iCAF1 and iCAF2 between PBS control
and artLCMV-TRP2-treated mice. i Real-time PCR analysis for Il33 expression in EYFP+ PDPNhi sorted cells from tumors of Cxcl13-Cre/tdTom EYFP mice.
ScRNA-seq analysis was performed with one biological replicate for n= 6 PBS-treated mice and two biological replicates for n= 3–4 artLCMV-TRP2-
treated mice. We obtained 1293 (PBS) and 786 (artLCMV-TRP2) EYFP-expressing cells. Dots in d, i represent individual mice and shown is mean+ s.e.m.
values. Pooled data from two independent experiments with n= 5 (PBS) and n= 6 (artLCMV-TRP2) mice (d); n= 10 (PBS) and n= 9 (artLCMV-TRP2)
mice (i). Statistical analysis was performed using unpaired two-tailed Student’s t test (d, i) with *P < 0.05: **P < 0.01; ***P < 0.001. Source data and exact P
values are provided in the Source data file.
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effector differentiation and prevents T cell exhaustion, hence
enabling curative melanoma treatment by LCMV-based viral
vectors.
Discussion
This study unveils an inducible intratumoral fibroblastic niche
that fosters the activity of antitumor CD8+ T cells. Single intra-
tumoral administration of a propagation-attenuated artLCMV
vector profoundly modulated the activation state of immunosti-
mulatory, Cxcl13-expressing FSCs in the TME. IL-33 was iden-
tified as a key factor provided locally by reprogrammed iCAFs
that fuels the activity of antitumor T cells and thereby facilitates
curative melanoma treatment.
Viral vectors are considered a promising means to activate and
mobilize antitumor T cells21,37. Oncolytic viruses, for example,
are used for cancer therapy because they directly lyse infected
tumor cells and subsequently induce an inflammatory immune
response38. Several disadvantages hinder the long-term efficacy of
oncolytic viruses in cancer therapy including type-I IFN-con-
strained replication of oncolytic viruses within tumor cells39,
limited selective targeting of tumor cells, or temporally restricted
viral persistence due to lysis of infected cancer cells40. In contrast,
LCMV is a highly immunogenic but non-cytopathic virus that
persists in long-lived host cells unless these cells are lysed by
CD8+ T cells41. Molecular modification of the artLCMV
genome30 allows for the incorporation of diverse tumor-derived
antigens, such as the melanoma-associated TRP2 antigen, to
induce tumor-specific T cell responses. Moreover, our study
shows that artLCMV-transduction of tumor-associated FSCs
















































































































































































































































































Fig. 6 Sustenance of antitumor T cell responses by FSC-derived IL-33. a Mice were inoculated s.c. with B16F10 melanoma cells and treated on day 7 i.t.
with artLCMV-TRP2. Frequency of ST2+ CD8+ T cells in the tumor and the TDLN at indicated time points. b Tumor growth kinetics and c survival in
Cxcl13-Cre Il33fl/fl and Cre-negative littermate mice (Ctrl) treated i.t. with artLCMV-TRP2 on day 7 after B16F10 inoculation. Dots indicate mean ± s.e.m. for
each time point. d–k Tumor-infiltrating T cells were analyzed by flow cytometry on day 15. d Frequency of tumor-infiltrating CD8+ and CD4+ T cells. e
Frequency of TRP2 tetramer+ CD8+ T cells and f KLRG1+ CD62L− CD8+ T cells. g IFN-γ- and TNF-α-producing tumor-infiltrating TRP2-specific CD8+
T cells. h Frequency of CD69+ CD8+ T cells. i Mean expression of Eomes, PD-1, TOX, and T-bet on tumor-infiltrating CD8+ T cells and j Frequency of PD-
1hi Eomeshi and k PD-1hi TOX+ among CD8+ T cells. Dots represent individual mice and lines indicate mean values. Pooled data from two independent
experiments with n= 8 (Day 11), n= 10 (Day 13) and n= 9 (Day 15) (a); n= 11 (PBS, Ctrl), n= 8 (PBS, Cxcl13-Cre Il33fl/fl), n= 9 (artLCMV-TRP2, i.t., Ctrl)
and n= 10 (artLCMV-TRP2, i.t., Cxcl13-Cre Il33fl/fl) mice (b, c); n= 8 (Ctrl) and n= 10 (Cxcl13-Cre Il33fl/fl) mice (f); n= 10 (Ctrl) and n= 8 (Cxcl13-Cre
Il33fl/fl) mice (g); n= 5 (Ctrl) and n= 10 (Cxcl13-Cre Il33fl/fl) mice (h); n= 7 (TOX, Ctrl) and n= 9 (TOX, Cxcl13-Cre Il33fl/fl) mice (i); n= 7 (Ctrl) and n
= 11 (Cxcl13-Cre Il33fl/fl) mice (k). Pooled data from three independent experiments with n= 10 (Ctrl) and n= 15 (Cxcl13-Cre Il33fl/fl) mice (d, e, j); n= 7
(PD-1, Ctrl), n= 9 (T-bet, Ctrl), n= 10 (Eomes, Ctrl) and n= 9 (PD-1, Eomes, T-bet, Cxcl13-Cre Il33fl/fl) mice (i). Statistical analysis was conducted using
one-way ANOVA with Tukey’s multiple comparison test (a), two-way analysis of variance (ANOVA) with Bonferroni (b), Log-Rank Mantel–Cox test (c) or
unpaired two-tailed Student’s t test (d–k) with *P < 0.05: **P < 0.01; ***P < 0.001. Source data and exact P values are provided in the Source data file.
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and that the vector-induced inflammatory milieu in the TME
controls the maintenance of antitumor immunity and tumor
regression.
Recent high-dimensional transcriptomic analyses have begun
to unravel the heterogeneity of the fibroblastic landscape in
healthy tissue and in different human and murine
tumors13,36,42,43. Our study confirms the existence of iCAFs and
myCAFs as two major tumor FSC subsets that are similar to
immune and desmoplastic CAFs42 and VEGF+ CAFs18. While
EYFP-labeled FSCs in Cxcl13-Cre/tdTom EYFP mice comprised
both iCAFs and myCAFs, current Cxcl13 mRNA expression was
almost exclusively restricted to iCAF2 in artLCMV-injected
tumors. Thus, the Cxcl13-Cre/tdTom EYFP mouse model facil-
itates the phenotypical characterization of immune-stimulatory
Cxcl13-expressing iCAFs in the TME and enabled the resolution
of the molecular circuits underlying the artLCMV-induced acti-
vation of tumor FSCs.
Our study delineates an intervention strategy to modulate both
the global composition of the fibroblastic TME and the functional
state of those fibroblasts that form immunostimulatory niches in
melanoma. It is mainly the iCAF population that is repro-
grammed by LCMV-based vectors to attract and sustain tumor-
infiltrating CD8+ T cells through: (1) increased intratumoral
accumulation of CD8+ T cells via type I IFN-induced chemo-
kines; (2) increased antigen presentation; and (3) prevention of
CD8+ T cell exhaustion by FSC-derived molecules, such as IL-33.
Moreover, the expression of the lymphocyte-attracting chemo-
kines Cxcl13 and Ccl19 in iCAF2 was significantly increased
following intratumoral artLCMV application, which might favor
the development of tertiary lymphoid structures and could
improve the efficacy of checkpoint inhibitor therapy44–46. Hence,
application of artLCMV should be considered as a treatment
option to harness the immunostimulatory capacities of repro-
grammed iCAFs in cancer entities that are amenable to check-
point inhibitor therapy and are accessible for intratumoral
delivery of the viral vector.
Fibroblasts are the most abundant cellular source of IL-33 in
many tissues including the skin and the lung47,48. In addition to
the dominant function of IL-33 in the induction of type-2
immunity, recent studies have assigned an important role of this
tissue cytokine during antiviral and antitumoral immune
responses49–51. Our finding that mice with Il33-deficiency in
Cxcl13-Cre+ FSCs exhibit impaired effector function of TRP2-
specific CD8+ T cells are in line with previous studies that
showed IL-33-dependent T cell effector differentiation27,52. The
increased expression of the exhaustion markers PD-1, Eomes, and
TOX on tumor-infiltrating CD8+ T cells in mice lacking intra-
tumoral IL-33 production by skin-derived Cxcl13-Cre+ FSCs is
consistent with the phenotype of terminally exhausted
T cells53–55. Hence, distinct FSC subsets in the melanoma TME
provide niches that support the functionality of antitumor T cells
and prevent exhaustive activation. Similar T cell activity-
supporting niches exist in other organs, such as the lung, where
perivascular FSCs support not only type 2 innate lymphoid
cells47, but sustain inflating memory CD8+ T cells in an IL-33-
dependent manner56. Thus, it appears that artLCMV-mediated
reprogramming of the fibroblastic TME triggers immune cell-
activating circuits that support local T cell responses in virally
infected peripheral tissues.
Overall, the present study provides evidence that immune
responses elicited by local artLCMV-TRP2 treatment are not
limited to the accessible injected tumor site but extend systemi-
cally as shown by the significant reduction of tumor growth in the
lung. Thus, reprogramming of the local tumor-associated fibro-
blastic stroma by artLCMV bolsters effector functions of tumor-
specific T cells that traffic to distant metastatic lesions to exert
systemic antitumor activity. Currently, artLCMV vectors are in
clinical trials for the vaccination of transplant patients against
cytomegalovirus infections32 (ClinicalTrials.gov Identifier
NCT03629080) and for the treatment of patients with human
papilloma virus-induced head and neck cancer (ClinicalTrials.gov
Identifier NCT0418021). Our study provides the rationale for the
intratumoral application of artLCMV vectors for other tumor
entities including melanoma. It will be important in future studies
to further elaborate whether and to which extent artLCMV-based
intratumoral vaccination can be combined with established
therapeutical approaches to foster and sustain antitumor T cell
activity in the inflamed TME and in distant metastatic lesions.
Methods
Mice. C57BL/6N (B6) mice were obtained from Charles River Laboratories
(Germany). Cxcl13-Cre/tdTomato crossed to R26R-EYFP reporter mice have been
previously described34,35. The Il33-targeting vector to generate the Il33fl/fl mice was
generated by the trans-NIH Knock-Out Mouse Project (KOMP Project ID
CSD88909) and obtained from the KOMP Repository (www.komp.org). To spe-
cifically ablate Il33 expression in FSCs, Cxcl13-Cre/tdTomato mice were crossed
with Il33fl/fl mice. Transgenic mice expressing the P14 T cell receptor specific for
the H-2Db-restricted epitope GP33-41 and CD45.1 as congenic marker were used as
organ donors for adoptive CD8+ T cell transfer experiments57. P14 TCR transgenic
mice crossed to Il1rl1 (ST2)-deficient mice. Il1rl1−/− P14 mice were used under
MTA from A. McKenzie (MRC, Cambridge, UK). All strains are on the C57BL/6
background and Cre-negative littermate controls were used as controls. All mice
were kept in a specific-pathogen-free condition and experiments were performed
with 6–10-week-old female age-matched mice. Experiments were performed in
accordance with federal and cantonal guidelines (Tierschutzgesetz) under per-
mission numbers SG08/17, SG01/18, SG07/19, SG04/20, and SG01/20 following
review and approval by the respective Cantonal Veterinary Offices (St. Gallen,
Switzerland).
Cells. B16F10 cells were obtained from ATCC and cultured in complete Dulbecco’s
Modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% FCS (Sigma-
Aldrich, St. Louis, Mo), 10 mmol/L NEAAs (Gibco), 1 mmol/L sodium pyruvate,
100 IU/ml penicillin/ streptomycin (Lonza, Basel, Switzerland). BHK-21 and
HEK293 cells are stable transfectants carrying plasmid M369 that expresses the
LCMV-glycoprotein (LCMV-GP) cDNA58. All cell lines were kept at 37 °C and 5%
CO2 in a humidified incubator and regularly examined for mycoplasma.
Generation of B16F10-Dct−/− and B16F10-mCherry cells. TRP2-deficient
B16F10 cells (B16F10-Dct−/−) were generated using CRISPR-Cas9 technology.
Sequences for the guide RNA (sgRNA exon 2, 5′GCTTCTTCCGAT
TACAGTCGGGG, Chr14; 118043326) were designed using the CHOPCHOP tool
(available at http://chopchop.cbu.uib.no/index.php)59,60. SgRNA were inserted into
the pSpCas9(BB)−2A-GFP (PX458) plasmid (Addgene, Plasmid #48138) expres-
sing Cas9 and EGFP. B16F10 cells were transfected with the sgRNA PX458 plasmid
targeting Dct (TRP2 gene). The Dct gene from cells expressing GFP was amplified
(forward 5′-GCCCCTTTTTAAATCAGGAAA, Chr14:118043303-118043325 and
reverse 5′-GTGATCACGTAGTCTGGATGGA, Chr14:118043127-118043149) and
a T7 endonuclease I (T7EI) assay was performed to, check genome-targeting
efficiency. After subcloning, single clones were again tested for deletion of Dct
using the T7EI mismatch detection assay. Sequencing and an intracellular flow
cytometric staining for the expressing of TRP2 protein (anti-TRP2/DCT ab74073,
abcam, and Alexa Fluor 488–conjugated anti-rabbit IgG, Jackson Immunotools)
confirmed the deletion of the Dct gene (Supplementary Fig. 1b). B16F10-mCherry
cells were generated by transduction of B16F10 cells with lentiviral vectors carrying
LeGO-C2 (Addgene, Plasmid #27339) expressing mCherry61.
Generation of recombinant artLCMV vectors. Propagation-attenuated recom-
binant LCMV-based vectors with an artificial genome organization (artLCMV)
were generated as described30,31. We inserted the full-length cDNA sequence of the
murine melanoma-associated antigen TRP2 or of the GFP into the small segment
of the LCMV genome. artLCMV vectors were generated by transient transfection
of BHK21 cells stably expressing the LCMV-GP as described58. Virus-containing
supernatant was harvested and FCS-free vector stock material was generated by
infecting a suspension of HEK293 cells with a MOI of 0.001 and incubation for 72
h. Nascent viruses were harvested after centrifugation of the cells and the infectious
titer was determined by focus forming assay30,31.
Tumor graft models and treatment with artLCMV vectors. Mice were inocu-
lated with 2 × 105 B16F10 melanoma cells s.c. into the flank or i.v. On day 7, when
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tumors became palpable (20–50 mm3), mice were treated either i.v. or i.t. with 1 ×
105 FFU artLCMV-TRP2 or artLCMV-GFP. Tumor size was measured with cali-
pers 2–3 times per week and tumor volume was calculated as width2 × length ×
0.562,63. Mice were sacrificed when tumor size exceeded 1000 mm3 or when mice
showed signs of illness. For re-challenge experiments, mice were injected on day
100 s.c. with 2 × 105 B16F10 melanoma cells into the opposite flank. For in vivo
ablation of CD8+ and CD4+ T cells, mice were injected i.p. twice per week with
250 μg of rat anti-CD8 (clone YTS169) or rat anti-CD4 (clone YTS191) antibody
starting 1 day prior to treatment with artLCMV-TRP2 and every third day after-
wards. Depletion of T cell subsets was monitored in blood. For adoptive T cell
transfer experiments, lymphocytes were isolated from spleens of P14 TCR tg
CD45.1 mice and tumor-bearing mouse received 1–2 × 105 P14 CD8+ CD45.1+
T cells i.v. In addition, mice were injected i.t. with 1 × 105 FFU artLCMV-TRP2.
Preparation of stromal cells and hematopoietic cells. For stromal cell isolation,
tumors and TDLNs were mechanically dissociated and collected in RPMI 1640
medium containing 2% FCS, 20 mM HEPES (Lonza), 1 mg/ml Collagenase P
(Roche), 25 μg/ml DNaseI (Applichem) and 0.8 U/ml Dispase I (Roche). Dis-
sociated tissue was incubated at 37 °C for 45 min, with resuspension and collection
of the supernatant every 15 min. Cell suspension was filtered and washed in PBS
containing 0.5% FCS and 10 mM EDTA. Stromal cells were enriched using CD45
and TER119 MACS microbeads (Miltenyi, Germany) to deplete hematopoietic cells
and erythrocytes.
For the isolation of tumor-infiltrating immune cells, tumors were mechanically
dissociated and disrupted on a 70 μm cell strainer (Falcon, Corning). Cells were
washed once and immune cells were collected at the interface using a Ficoll
gradient (Lympholyte M, CedarLane). Lymph nodes and spleens were gently
smashed on a 70 μm cell strainer. Cell suspensions were directly used for flow
cytometric analysis or cell sorting.
Ex vivo restimulation and cytokine production. For the assessment of ex vivo
cytokine secretion, mice were injected i.p. with 250 μg Brefeldin A (Sigma-Aldrich)
in and euthanized 4 h later64. Subsequent processing of tissues and staining was
performed in the presence of 10 μg/ml Brefeldin A. Lymphocytes were resuspended
in RMPI 1640 containing 5% FCS and stimulated with 10−6 M of the TRP2180-188
(SVYDFFVWL) H2-Kb and LCMV-NP396–404 (FQPQNGQFI) or LCMV-GP33-41
(KAVYNFATC) H2-Db peptides or with 2 μg/ml TRP2 15-mer over-lapping
peptide pools in the presence of 10 μg/ml Brefeldin A for 5 h at 37 °C.
Human participants and preparation of human cells. Patient samples were
obtained from the Department of Plastic Reconstructive Surgery and the Depart-
ment of Dermatology at the Kantonsspital St. Gallen. The study has been approved
by the ethics committee of Eastern Switzerland (EKOS16-079, BASEC Nr. 2016-
00998) and all patients provided a written informed consent. Skin specimens were
taken from healthy patients undergoing abdominoplasty (female and male, age
18–61). Melanoma tissue was obtained from punch biopsies from a primary tumor
of a melanoma patient. Skin and melanoma fibroblasts were isolated using the
MACS Whole Skin Digestion kit (Miltenyi, Germany). Fibroblasts were cultured in
RPMI 1640 with 5% FCS, 1 mmol/L sodium pyruvate, and 16 μg/ml gentamycin.
Patient-matched peripheral blood mononuclear cells (PBMCs) were isolated using
a Ficoll-Paque gradient centrifugation and cells were cryopreserved in 90% FCS
and 10% DMSO. PBMCs were seeded in a 24-well plate at a density of 1 × 106 cells/
well and fibroblasts at a density of 1 × 105 cells/ well. On the following day, cells
were infected with artLCMV at an MOI of 1 and incubated for 48 h. Cells were
fixed for immunohistochemistry or detached for flow cytometric analysis.
Flow cytometry. Single cells suspensions were incubated in PBS containing 0.5%
FCS and 10 mM EDTA with the indicated antibodies (Supplementary Table 1) for
20 min at 4 °C. For the identification of tetramer-binding CD8+ T cells, cells were
stained with PE-labeled H-2Kb-TRP2180–188 tetramer (MBL, Woburn, MA) for 10
min at 37 °C. For discrimination between live and dead cells, single-cell suspen-
sions were stained with AQUA-BV510 or e780 in PBS prior to antibody staining
(Molecular Probes) or by adding 7AAD prior to acquisition (Calbiochem). For
intracellular or intranuclear staining, cells were fixed and permeabilized using the
BD Cytofix/Cytoperm (BD Biosciences) or the FoxP3 Transcription Factor
(eBiosciences) kits, respectively. The anti-LCMV-NP antibody was conjugated with
AF657 or AF594 (Antibody Labeling Kit, ThermoFisher). Cells were acquired with
a BD LSRFortessa (BD Biosciences) and data analysis was performed using FACS
Diva (BD Bioscience, v8.0.1) and FlowJo (Treestar Inc., v10). Cells were sorted on a
Biorad S3 (Biorad) or BD Melody Cell Sorter and data were analyzed using
FACSChorus (BD Biosciences, v1.3).
Immunohistochemistry. Tumors were harvested and fixed overnight at 4 °C in
freshly prepared 4% paraformaldehyde (Merck Milipore) under agitation. Tumors
were put overnight in 30% and 15% sucrose in 1xPBS, respectively and frozen in
OCT. Serial sections were cut at a thickness of 8–12 μm using a cryotome. Cell
layers of artLCMV-infected or uninfected human skin fibroblasts were fixed for 10
min with 4% PFA. Sections were blocked in PBS containing 10% FCS, 1 mg/ml
anti-Fcγ receptor (BD Biosciences) and 0.1% Triton X-100 (Sigma). Sections were
incubated with the following primary antibodies for 1–2 h at room temperature:
anti-PDPN or anti-PDPN-bio (Clone eBio8.1.1, BioLegend, 1:200), anti-GFP
(Aves, 1:1000), anti-mIL-33 (R&D systems, 1:500), AF647-conjugated anti-LCMV-
NP (Clone BE0106, BioXcell, 1:200), Cy3-conjugated anti-αSMA (Clone 1A4,
Sigma, 1:400), and FITC-conjugated CD90 (Clone 5E10, BioLegend, 1:100).
Unconjugated antibodies were detected with the following secondary antibodies:
AF488-conjugated anti-chicken-IgG (Thermofisher, 1:1000), Dylight549-
conjugated anti-syrian hamster-IgG, AF647-conjugated anti-goat IgG, AF488-
conjugated Streptavidin (all from Jackson Immunotools, 1:500 to 1:1000). Analysis
was performed using a confocal microscope (LSM-710, Carl Zeiss) and the ZEN
2010 software (Carl Zeiss, v14.0.18.201). For image analysis Imaris version 9
(Bitplane) was used.
Single-cell RNA-seq analysis. cDNA libraries from sorted EYFP+ or PDPN+
FSCs were generated on a 10x Chromium Controller (10x Genomics)65 according
to the Chromium Single-Cell 3′ Reagent Kit (v2 Chemistry) in three samples (one
PBS-treated and two artLCMV-treated samples). Sequencing was run on a
NovaSeq 6000 sequencing system from Illumina at the Functional Genomic Center
Zurich. Initial processing of sequencing files was done running CellRanger
(v2.1.1)66 count with the Ensembl GRCm38.94 release as a reference and followed
by a further quality control run in R v3.6.1 using functions from the R/Bio-
conductor packages scater (v1.13.15)67 and SingleCellExperiment (v1.7.4)68. This
quality control included the removal of damaged and contaminating cells based on
(1) very high or low UMI counts (>2.5 median absolute deviation from the median
across all cells), (2) very high or low total number of detected genes (>2.5 median
absolute deviation from the median across all cells), (3) high mitochondrial gene
content (>2.5 median absolute deviations above the median across all cells), (4)
expression of one of the contamination markers Pecam1, Pmel, Cd52, or Tyrp1, (5)
high expression of any of the genes Hba-a1, Hba-a2, Krt18, or Lyve1. Finally, only
cells expressing mRNA encoding for the EYFP gene were retained for further
analysis resulting in a dataset of 1293 cells from PBS control samples and 786 cells
from artLCMV-treated samples. Downstream analysis was performed using
functions from the Seurat package (SeuratWrappers, v3.1.0)69 and included nor-
malization, scaling, dimensional reduction with PCA and UMAP and graph-based
clustering. Cluster characterization was done based on the expression of canonical
marker genes as well as cluster markers calculated with the FindMarkers function
of the Seurat package. In order to compare expression profiles between artLCMV-
treated and PBS control samples differentially expressed genes were inferred from
Wilcoxon test, again using the FindMarkers function of the Seurat package. For
functional interpretation top differentially expressed genes were summarized to
functionally gene signatures based on their reported gene functions. Next, cells
were projected on a diffusion map70 by utilizing the runDiffusionMap function
from the scater R/Bioconductor package (v1.16.2)67 and functional gene signatures
were visualized as average expression across all genes of a signature.
RNA isolation and quantitative real-time PCR analysis. RNA from sorted cells
was isolated using the RNeasy Mini Kit (Qiagen). Total mRNA was extracted from
organs by TRIzol (Ambion) using the Direct-zol RNA Kit (ZYMO Research, USA).
Contaminating DNA was eliminated through on-column DNase digestion (Zymo
Research) and cDNA was generated using Quantitect Reverse Transcription Kit
(Qiagen, USA). RT-PCR amplification of LCMV-NP (forward 5′ACTGACG-
GAGGTCAACCCGG, reverse 5′CAAGTACTCACACGGCATGGA), Ccl19
(QT02532173), Cxcl13 (QT00107919), Il33 (QT00135170), and the housekeeping
genes Hprt (QT00166768) and TATA-binding protein (Tbp, QT00198443, all
Qiagen) was performed in duplicates using the SYBR Green Master Mix (Applied
Biosystems, Darmstadt, Germany) on a QuantStudio5 machine (Thermo Fisher,
Analysis Software v1.5.1). Relative gene expression analysis was calculated using
the ΔΔCt method71. The threshold cycle for LCMV-NP >30 cycles was determined
as limit of detection.
Statistical analysis. Statistical analysis was performed using Prism8 (GraphPad).
Unless specified otherwise, graphs depict mean ± s.d. or s.e.m. Differences between
two groups were evaluated using unpaired two-tailed Student’s t-tests. Single values
of multiple groups were compared by one- or two-way analysis of variance
(ANOVA), followed by Tukey’s multiple comparison test or Bonferroni post hoc
test. Kaplan–Meier Survival curves were assessed using Log-Rank Mantel–Cox test.
Results were considered statistically significant when *P < 0.05, **P < 0.01, and
***P < 0.001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
scRNA-seq data are available in the ArrayExpress database with accession number:
E-MTAB-9407. Ensembl GRCm38.94 was used as a reference to build index files for
alignments in scRNA-seq analysis. The remaining data are available within the Article,
Supplementary Information or Source Data file. Source data are provided with this paper.
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